Prof. Sun Young RHA Yonsei University College of Medicine Korea Link to biosketch

Abstract

With accumulation of immune-genomic information, precision medicine, including targeted and immunotherapy, is becoming feasible in many cancers. However, the progress of precision medicine in metastatic gastric cancer is very slow and only a limited subpopulation is getting benefit from targeted and immunotherapy. The potential reasons for these limitations are 1) tumor heterogeneity and difficulties in proper sample availability, 2) proper target identification with target validity, 3) drug efficacy and availability, and 4) complex clinical behavior with unproven biology behind. Based on TCGA molecular classification, current NGS technology makes it feasible for proper subgrouping and selecting each patient’s molecular subgrouping. Now we have more opportunities for precision medicine in GC including biomarker-driven umbrella trial.

Here, I will share the first report of K-Umbrella gastric cancer study; an open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer. I will also share the challenges and opportunities in performing umbrella trial in gastric cancer. Our cooperative and integrative effort will support precision medicine in reality.